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Expression of TGF-1 and matrix proteins is elevated in rats
with chronic rejection
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Expression of TGF-131 and matrix proteins is elevated in rats with
chronic renal rejection. The pathogenesis of fibrosis in chronic renal
allograft rejection remains unknown. Since TGF-131 plays a key role in
fibrogenesis, we studied a rat model of chronic allograft rejection that
shows similarities to the structural lesion described in patients. We
previously demonstrated an increased expression of TGF-pl in human
kidney biopsies with acute and chronic rejection. Recipients of renal
allografts (F344-Lewis) and isografts (Lewis-Lewis) were sacrificed at 4, 8,
24 and 52 weeks. Characteristic histologic changes of chronic rejection
developed in the allografts as early as four weeks and were accompanied
by progressive albuminuria significant by eight weeks. Allografts showed a
progressive increase in mRNA expression of TGF-31 and matrix proteins
during the 52 week course. Increased matrix deposition by immunofluo-
rescence was mostly present in the interstitium and vessels early and in all
kidney compartments later. The mRNA expression of plasminogen acti-
vator inhibitor, a protease inhibitor stimulated by TGF-131, increased
along with TGF-f31 and matrix proteins. These results suggest that the
fibrosis of chronic renal allograft rejection is mediated, at least partly, by
the dual action of TGF-pl on matrix deposition and degradation.
Despite progressive improvements in the short-term outcome
of transplantation, the annual rate of long-term graft loss has
remained virtually unchanged [1, 2]. The most important cause of
late graft attrition after the first year of transplantation is a poorly
understood clinicopathological entity called "chronic rejection"
and more correctly referred to as "chronic allograft nephropathy"
since the exact nature of the process is unclear. It remains the
single most important cause of graft loss after the first year [3—5].
Renal transplants with chronic rejection exhibit a gradual and
progressive deterioration in function in association with protein-
uria and hypertension [6]. The histology of chronic rejection in
renal allografts is characterized by arterial intimal and medial
fibrosis and arteriolar insudative lesions, glomerulosclerosis and
interstitial fibrosis with tubular atrophy [7]. There is also a
variable amount of tissue infiltration with T cells and macro-
phages [8, 9].
The pathogenesis of chronic rejection remains unknown [3—5].
Recent studies have shown that acute rejection is an important
risk factor for chronic rejection [10, 11]. The role of HLA
matching was also advanced as supporting an immunologic basis
since the incidence of chronic rejection is lower in grafts from
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living related donors [12]. However, those grafts usually have a
short ischemia time and immediate graft function which correlate
with a better outcome. Although intense immunosuppression is
useful in reversing acute rejection, it is ineffective in chronic
rejection [13]. As a result, other non-immunological factors are
thought to operate in the progressive deterioration of the allograft
[14—16]. Independent of initiating events, the cause of tissue
destruction in chronic rejection is fibrogenesis, or accumulation of
extracellular matrix (ECM), which also occurs in chronic diseases
of the kidneys and other organs [17—19]. Excess ECM accumula-
tion ultimately leads to loss of allograft renal function.
The lack of a reproducible animal model of chronic rejection
has hampered the study of the mechanisms involved in this
disease. Recently, a previously described model of chronic renal
rejection was reproduced and adapted [20]. Striking similarities
between this model and the changes observed in the grafts of
many patients with chronic rejection were reported [21]. A
mononuclear cellular infiltrate was also shown to be present. A
number of cytokines, presumably derived from this cellular infil-
trate, were shown to be expressed suggesting an immunologic role
for the development of chronic rejection in this model [22, 231.
However, nephron supply also seems to play a role in long term
outcome in this model [24]. In addition, if allografts are retrans-
planted into the donor within 12 weeks, the histologic changes are
reversed indicating that, while immunologic factors are operating
early on, they do not play a role in the later stages of the disease
[25].
To date, no study has looked at the components of the fibrotic
lesion of chronic rejection in this model and none has attempted
to correlate the renal fibrosis or the expression of ECM compo-
nents with any growth factor. Since transforming growth factor-/3
(TGF-p) is a key fibrogenic cytokine, we hypothesized that TGF-/3
overexpression might be responsible for the fibrosis of chronic
rejection in this model. TGF-J3 has been implicated in the fibrosis
of a number of chronic diseases of the kidney and other organs
[26, 27]. TGF-13 directly stimulates the synthesis of individual
ECM components [28—31]. It also blocks ECM degradation by
decreasing the synthesis of proteases and stimulating protease
inhibitors like plasminogen activator inhibitor-i (PAl-i) [32—34].
In addition to its effect on matrix accumulation, TGF-p also
promotes immune suppression [26, 35, 36].
Our findings in this paper indicate that all representative
components of the ECM are elevated in this model and that their
expression correlates with an increased expression of TGF-pl and
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PAl-I. These results suggest that the ECM accumulation ob-
served in this model of chronic renal allograft rejection likely
involves the dual action of TGF-J3 on increasing ECM deposition
and decreasing ECM degradation.
Methods
Experimental design
Inbred adult male rats, weighing 250 to 300 g were used in all
experiments (Charles River, Wilmington, MA, USA). Lewis rats
(LEW RT1') acted as recipients for the allografts and as donors
and recipients for the isografts. Fisher rats (F344, RT11) acted
as donors for the allografts. These rats differ partially at MHC
classes I and II, and various non-MHC genes. Donor rats were
anesthetized with an i.p. injection of chioral hydrate (300 mg/kg).
The left kidney, left ureter and dome of the bladder were
removed, then flushed and cooled in cold Collins' solution. The
kidney was then positioned orthotopically in anesthetized, weight-
matched Lewis recipients after the recipient left kidney vessels
were mobilized, clamped and the native kidney excised. The
donor and recipient renal artery, vein and ureter were each then
anastornosed end-to-end with 10-0 prolene sutures without ure-
teral stenting [37]. The contralateral right native kidney was
removed at day 10. All animals (allografts and isografts) received
a short course of cyclosporine A 5 mg/kg/day (Sandimmune®;
Sandoz Research Institute, East Hanover, NJ, USA) i.m. for 10
days after transplant to prevent early rejection which would
otherwise prove fatal. All recipients received a single i.m. injection
of 100,000 units of penicillin G (Pfizer, New York, NY, USA) at
the time of grafting as prophyl axis for wound infection. Functional
studies were done at 2, 4, 8, 12, 16, 24 and 52 weeks (see below)
and animals were sacrificed at 4, 8, 24 and 52 weeks (N = 5 in each
group). Animals were anesthetized with ketamine and the abdo-
men was opened through a midline incision. With the aorta
occluded by ligation above the renal artery and the renal vein
opened by a small incision for outflow, the transplanted kidney
was perfused with 20 ml of cold heparinized saline. The kidney
was removed, the cortex was carefully dissected from the medulla,
and tissues were processed for evaluation by light microscopy,
RNA analysis and immunohistochemistry.
Functional studies
Blood was sampled from the rat tail vein and 24-hour quanti-
tative urine samples were collected in metabolic cages (Nalge Co.,
Rochester, NY, USA). Serum and urine creatinine were deter-
mined colorimetrically by using creatinine reagents (Sigma Chem-
ical Co., St. Louis, MO, USA) after appropriate dilutions were
done. To determine urine albumin, an inhibitory ELISA tech-
nique modified from the method of Rennard et al was used [38].
Wells in one microtiter plate were coated with rat serum albumin
(Sigma Co., St. Louis, MO, USA). To another plate, known serial
dilutions of serum albumin or unknown samples and rabbit IgG
anti-rat albumin (Cappel, Durham, NC, USA) were added. After
washing the coated plate, aliquots of the second plate were added
to the coated plate and incubated. After washing, horseradish
peroxidase-conjugated goat anti-rabbit IgG (Pierce, Rockford, IL,
USA) was added and developed using standard methods. The
absorption of the colored reaction product was then measured in
a microtiter plate reader (Molecular Devices, Menlo Park, CA,
USA) at 450 nm. The creatinine clearance was calculated using a
standard formula.
Morphology
Renal tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Two to four micron thick sections were
stained with periodic acid-Schiff's reagent (PAS) and Trichrome.
The histologic findings were subdivided into three categories:
glomerulosclerosis, tubulointerstitial fibrosis and arteriolopathy.
Glomeruloscierosis was defined by increased mesangial matrix
without increased cellularity and also loss of capillary patency.
Features of interstitial inflammation were mononuclear and lym-
phocytic infiltrates and edema. Findings of scarring were matrix-
rich expansion of the interstitium with distortion of the tubules
and thickening of the tubular basement membranes. Renal arte-
rial and arteriolar lesions were characterized by hyalin deposition
within the tunica media of arterioles, hypertrophy of the vessel
wall, and perivascular cellular infiltrates and fibrosis. A minimum
of 20 fields at bOX and 250X magnifications were assessed and
graded with a minimum of two sections in each biopsy by an
observer masked to treatment groups using a color image analyzer
(Carl Zeiss, Inc., Oberkochen, Germany).
The following semiquantitative score was used to assess the
extent of changes in each category. For glomerulosclerosis, the
percentage of each glomerulus occupied by mesangial matrix and
the number of obliterated capillary lumina was estimated and
assigned a semi-quantitative score using the following: 0 =<25%
glomerulosclerosis, 1 = 25 to 50%, 2 = 50 to 75% and 3 = 75 to
100%. Tubulointerstitial fibrosis was estimated by assigning the
following scores: 0 = normal interstitium and tubules, 1 = mild to
moderate fibrosis with mild interstitial thickening between tu-
bules, 2 = moderate fibrosis with interstitial thickening between
tubules and minimal tubular dilation, 3 = severe fibrosis with
tubular dilation, significant interstitial thickening between tubules
and tubular basement membrane thickening. Arteriolopathy was
semiquantitatively determined by the following: 0 = < 15%
arterioles injured, 1 = 15 to 30% arterioles injured, 2 = 31 to 75%
and 3 = > 75% injured.
RNA analysis
After separating cortex from medulla, the tissue was finely
minced with a razor blade on ice. Total RNA was prepared by lysis
in 4 M guanidine isothiocyanate containing 1% 2-mercaptoethanol
and 0.5% lauryl sarcosyl and ultracentrifugation of the lysate on a
cesium chloride cushion. After rcsuspending in Tris-EDTA
buffer, RNA concentrations were determined using spectropho-
tometric readings at Absorbance76. Thirty micrograms of RNA
were electrophoresed in each lane of 0.9% agarose gels containing
2.2 M formaldehyde and 0.2 M Mops (pH 7.0) and transferred to
a nylon membrane (ICN Biochemical, Inc., Costa Mesa, CA,
USA) overnight by capillary blotting. Nucleic acids were
crosslinked by ultraviolet irradiation (Stratagene, La Jolla, CA,
USA). The membranes were prehybridized for two hours at 42°C
with 50% formamide, 10% Denhardt's solution, 0.1% SDS, 5x
standard saline citrate (SSC), and 200 jig/ml denatured salmon
sperm DNA. They were then hybridized at 42°C for 18 hours with
eDNA probes labeled with 32P-dCTP by random oligonucleotide
priming (Boehringer Mannheim Corp., Indianapolis, IN, USA).
The blots were washed in 2 X SSC, 0.1% SDS at room tempera-
ture for 15 minutes and in 0.1 X SSC, 0.1% SDS at 50°C for 15
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Weeks after
transplantation Allografts Isografts P value
2 0.6 0.1 0.4 0.1 NS
4 0.8 0.2 0.4 0.1 <0.05
8 0.8 0.2 0.4 0.1 NS
12 0.6 0.2 0.4 0.1 <0.05
16 0.6 0.2 0.4 0.1 NS
24 0.6 0.1 0.5 0.1 NS
52 2.1 0.1 0.6 0.0 <0.001
minutes. Films were exposed at —70°C for different time periods
to ensure linearity of densitometric values and exposure time.
Autoradiographs were scanned on a laser densitometer (Ultra-
scan XL; Pharmacia LKB Biotechnology, Inc., Bromma, Sweden).
The density of bands for the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA was used to control for differences
in the total amount of RNA loaded onto each gel line. For
quantitative purposes, the values were divided by the density of
bands for GAPDH in the same lane. The following probes were
used for Northern blot analysis.
A mouse TGF-131 eDNA probe (plasmid MUI5) was kindly
provided by R. Derynck [39]. A rat PAl-i eDNA probe [plasmid
pBluescript SK(-)j was obtained from T.D. Gelehrter [40]. Plas-
mid P16, which contains a human biglycan insert, was a gift of
L.W. Fisher [411. A rat decorin eDNA probe (plasmid pGEM4)
was provided by K.L. Dreher [42]. A rat procollagen al cDNA
(plasmid paiRl) was obtained from D. Rowe [43]. A rat GAPDH
eDNA probe (plasmid pBluescript KS II) was a generous gift from
J.M. Blanchard [44].
Immunohistochemistiy
Immunofluorescence microscopy was performed on tissues
snap frozen in cold isopentane with a cryostat microtome (Miles
Scientific, Naperville, IL, USA) as previously described [45]. Four
micrometer cryostat sections were fixed in acetone and washed in
PBS, pH 7.4. The deposition of the following ECM components,
decorin, tenascin and fibronectin-cellular containing extra domain
A (fibronectin EDA+) was determined. The primary antibody for
decorin was a rabbit anti-human decorin antibody and was kindly
provided by E. Ruoslahti (La Jolla, CA, USA) [46]. The other
primary antibodies used were rabbit anti-human tenascin (Life
Technologies, Gaithersburg, MD, USA) and mouse anti-human
fibronectin EDA+ (Sera-lab, Crowley Down, UK). The secondary
antibodies used were fluorescein isothiocyanate (FITC)-conju-
gated F(ab')2 donkey anti-rabbit IgG (Jackson Immunoresearch,
West Grove, PA, USA) and FITC-conjugated F(ab')2 rat anti-
mouse IgG (Jackson Immunoresearch). A minimum of 20 ran-
domly selected areas per sample were observed at x250 magni-
fication. The severity of staining for the glomerular,
tubulointerstitial and vascular compartments was evaluated by an
observer blinded to the treatment groups using the following
semiquantitative scale: 0 = diffuse, very weak or absent staining,
1 = staining involving less than 25%, 2 = staining involving 25%
to 50%, 3 = staining involving 50% to 75% and 4 = staining
involving 75% to 100%. Photographs were obtained at identical
exposure and development time intervals.
Weeks after transplantation
Fig. 1. Urine albumin excretion in both allografts (U) and isografts (11])
during the course of this 52-week model. Significant differences in albumin-
uria between isografts and allografts were evident as early as eight weeks
(29.0 vs. 46.8 mg/day, respectively). By 24 weeks, there was nearly a
threefold increase in albuminuria in allografts (138.2 vs. 48.4 mg/day in
isografts) and by 52 weeks, albuminuria had risen to 238.7 mg/day in
allografts versus 41.0 mg/day in isografts, which represents a sixfold
increase over controls. N = 3 to 5 for each group. *p < 0.05, < 0.01
and *** < 0.001 compared to isografts.
Statistical analysis
Results are presented as mean SEM. Multiple comparisons
were done by analysis of variance. Comparisons between allo-
grafts and isografts were done by two-tailed unpaired Student's
t-test or Mann-Whitney test, as appropriate. The level of statistical
significance was chosen as P < 0.05.
Results
Physiologic studies
Body weight gain was progressive and comparable in the
allografts and isografts throughout the study. Changes in body wt
between the start of the experiment and sacrifice remained similar
in control and experimental groups and did not achieve statistical
significance. Serum creatinine level was significantly elevated at 4
and 12 weeks in the allografted rats (0.8 0.2 vs. 0.3 0.1 mg/dl,
P < 0.05, 4 weeks; 0.6 0.2 vs. 0.3 0.1, P < 0.05, 12 weeks).
However, it remained equivalent between the two groups for the
duration of the study at weeks 16, 20 and 24 and did not become
again statistically significant (P < 0.001) until 52 weeks when it
rose to 2.1 0.1 mg/dl in the allografts versus 0.5 0.0 mg in the
isografts (Table 1). Creatinine clearance was calculated at 2, 4, 8,
24 and 52 weeks and was consistently worse in the allografts
without reaching, however, statistical significance until 52 weeks
(P < 0.001) (data not shown). Significant differences in albumin
excretion between isograft and allograft recipients were evident as
early as eight weeks after transplant (29.0 vs. 46.8 mg/day,
respectively, P < 0.05; Fig. 1). By 24 weeks, there was nearly a
threefold increase in urine albumin excretion in the allografts
(138.2 vs. 48.4 mg/day, P < 0.05) and by 52 weeks, urine albumin
excretion had risen to 239 mg/day in the allografts versus 41
mg/day in the isografts (P < 0.001), which represents a sixfold
Table 1. Serial serum creatinine values during the 52 week model
Values are mean SCM of 5 rats.
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Fig. 2. Histologic changes in experimental chronic renal allograft rejection. Micrograph showing the renal cortex of an allograft sacrificed at 52 weeks after
transplantation. There is evidence of segmental glomerulosclerosis and interstitial fibrosis with tubular atrophy. A mononuclear cellular infiltrate is also
observed. The vessel shown is mildly thickened with perivascular fibrosis (periodic acid-Schiff, magnification x 10).
increase over control. These values are consistently higher than
values observed in age-matched normal Lewis rats whose urine
albumin excretion can vary between 0.5 and 1.5 mg/day.
Histologic changes
The allografts had characteristic morphologic findings similar
to the human chronic rejection lesion. These changes were mostly
present by 24 weeks (Fig. 2) but were evident as early as four
weeks after engraftment. Allografts exhibited a gradual and
significant increase in segmental and global glomeruloscierosis.
There was progressive tubulointerstitial fibrosis with tubular
atrophy associated with thickening of the tubular basement mem-
brane and Bowman's capsule. In addition, a variable degree of
interstitial mononuclear cell infiltrate was observed. The vascular
lesion was characterized by hyalin deposition within arterioles,
hypertrophy of vessel walls, and perivascular cellular infiltrates
and fibrosis. The extent of changes was graded using a 0 to 3+
semiquantitative scale with 3 + indicating extensive changes.
Table 2 summarizes the histological scoring observed in this
model. Histologic changes of chronic rejection in the allografts
were evident as early as four weeks after transplantation and
remained significant when compared to the isografts throughout
the study period. Between weeks 16 and 52, a relatively high
mortality rate in the allograft rats was observed in our study
Table 2. Semiquantitative scoring by light microscopy of the extent of
changes observed in the chronic allograft and isograft kidneys for
glomerulosclerosis, tubulointerstitial fibrosis and arteriolopathy
Tubulointerstitial
Week
Glomerul
A
osclerosis
I
fibrosis
A I
Arteriol
A
opathy
I
4 0.6 0.OC 0.0 0.0 2.8 0.5u 0.4 0.1 1.3 0.3k 0.4 0.2
8 0.6 0.OC 0.1 0.1 2.9 Ol 0.5 0.4 1.2 03 0.3 0.0
24 1.1 0.2 0.3 0.2 2.6 0.2k 0.2 0.2 1.2 0.1C 0.1 0.1
52 1.1 0.3 1.0 0.1 3.7 0.1C 0.4 0.1 1.5 0.IIC 0.4 0.1
Values are mean SEM of 5 rats. Abbreviations are: A, allografts; I,
isografts.
C P < 0.05, P < 0.01 and C P < 0.001 vs. isografts
probably because of worsening histology. As a result, only the less
diseased allograft rats were studied. We observed a progressive
glomerulosclerosis in the isografts in a manner similar to what has
been described in aging and uninephrectomized rats. This pro-
gressive glomeruloscierosis in the isografts, coupled with the high
mortality rate observed in the allografts, may explain the lack of
significant glomerular changes at 52 weeks when comparing the
allografts to the isografts. However, significant glomerulosclerosis
was observed in the allografts versus the isografts as early as four
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Weeks after transplantation
Fig. 3. Quantitation of mRNA expression of TGF-pl in allografts relative to
isografts. Total RNA was isolated from whole cortex at weeks 4, 8, 24 and
52 and was hybridized with eDNA probes to TGF-131. Band densities for
GAPDH mRNA were used to control for differences in total amount of
RNA loaded onto each gel line. Values obtained for allografts were then
divided by values obtained for isografts and expressed as fold-increase in
mRNA. N = 5 for each group, *p < 0.05, < 0.01 and *** < 0.001
compared to isografts. Abbreviations are: A, allografts; I, isografts.
weeks (P < 0.001) and up to 24 weeks (P < 0.001). On the other
hand, the degree of tubulointerstitial fibrosis and arteriolopathy
remained significant throughout the study period (P < 0.05 at
weeks 4 and 8, < 0.001 at week 24 and < 0.01 at week 52) when
compared to isografts.
Expression of TGF-131 and PAl-i mRNA
The expression of TGF-131 mRNA in the cortex of the allografts
was elevated by week 4 (P < 0.05) when compared to isografts and
more so by weeks 8 and 24 (P < 0.001) and week 52 (P <0.01; Fig.
3). The mRNA expression of PAl-I, a protease inhibitor that
blocks ECM degradation by the plasmin protease system and that
is directly stimulated by TGF-f3, is shown in Figure 4. PAl-I
mRNA, in parallel to TGF-j31 mRNA expression, was consistently
up-regulated in allografts as compared to isografts but reached
statistical significance only at 8 (P < 0.001) and 52 weeks (P <
0.05).
Extracellular matrix deposition in the kidney
Northern blot analysis. The proteoglycans biglycan and decorin
are components of the ECM directly regulated by TGF-f3. Their
mRNA expression was elevated suggesting active matrix synthesis
(Fig. 5). Biglycan mRNA followed closely TGF-f31 mRNA expres-
sion and was significantly elevated both in the early follow-up
period at weeks 4 (P < 0.05) and 8 (P < 0.001), and later at weeks
24 (P < 0.01) and 52 (P < 0.05). The mRNA expression of
decorin (Fig. 5) was also statistically elevated in the allografts in a
manner similar to that of biglycan (week 4, P < 0.05; weeks 8, 24
and 52, P < 0.01). Type I collagen is normally present in the
interstitium of the kidney and is directly increased by TGF-p. In
this model, the mRNA expression of type I collagen (Fig. 6) was
Weeks after transplantation
Fig. 4. Quantitation of mRNA expression of PA I-I in ailografts relative to
isografts. Total RNA was isolated from whole cortex at weeks 4, 8, 24 and
52 and was hybridized with eDNA probes to PAT-i. Band densities for
GAPDH mRNA were used to control for differences in total amount of
RNA loaded onto each gel line. Values obtained for allografts were then
divided by values obtained for isografts and expressed as fold-increase in
mRNA. N = 5 for each group, ***p < 0.001 compared to isografts.
Abbreviations are: A, allografts; I, isografts.
similar to TGF-pl and PAl-i mRNA expression and was in-
creased at all time periods, with its expression reaching statistical
significance at weeks 4 (P < 0.01), 8 (P < 0.001) and 52 (P < 0.01)
in the allografts versus isografts.
Immunohistochemistty. To assess whether the increased mRNA
expression was translated into increased synthesis and deposition
of matrix proteins, certain components of the ECM were identi-
fied by immunofluorescence. This also allowed us to determine
which kidney compartments (glomeruli, vessels or tubulointersti-
tium) were most extensively involved in matrix expansion. We
examined the expression of tenascin, fibronectin EDA+, and
decorin. The amount of tenascin and fibronectin EDA+ was
elevated in the allografts as compared to isografts in all kidney
compartments and at all time intervals (Figs. 7 and 8). The
changes were most significant in the tubulointerstitium for both
tenascin (P < 0.01 at weeks 4 and 24 and <0.001 at weeks 8 and
52) and fibronectin EDA+ (P < 0.01 at weeks 4, 8 and 24 and
<0.05 at week 52; Fig. 8). The observed arteriolar hyalinosis
correlated with a progressive and significant increase in the
expression of tenascin and fibronectin EDA+ in the vessels of the
allografts. While it was not significant at four weeks, it reached
statistical significance at weeks 8 (P < 0.001 for tenascin
and < 0.05 for fibronectin EDA+), 24 (P < 0.01) and 52 (P <
0.01) when compared to isografts (Fig. 8). Most of the changes
reached statistical significance in the tubulointerstitial and vascu-
lar compartments of the kidney in accordance with the character-
istic histology of chronic allograft rejection. In the glomeruli, none
of the changes were statistically significant except early at 4 weeks
(P < 0.01) and later at 52 weeks (P < 0.001; Fig. 8).
The deposition of decorin followed its mRNA expression and
that of tenascin and fibronectin EDA+ (Figs. 7 and 8). Most of
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Weeks after transplantation
Fig. 5. Quantitation of mRNA expression of the proteoglycans, biglycan )
and decorin (i:Il) in allografts relative to isografts. Total RNA was isolated
from whole Cortex at weeks 4, 8, 24 and 52 and was hybridized with CDNA
probes to higlycan and decorin. Band densities for GAPDH mRNA were
used to control for differences in total amount of RNA loaded Onto each
gel line. Values obtained for allografts were then divided by values
obtained for isografts and expressed as fold-increase in mRNA. N = 5 for
each group, *p < 0.05, < 0.01 and *** < 0.001 compared to
isografts. Abbreviations are: A, allografts; I, isografts.
the changes in the allografts were observed at 24 and 52 weeks
(P < 0.01) but were statistically significant also at 4 and 8 weeks
(P < 0.05) when compared to the isografts.
Discussion
We have previously shown an elevated expression of TGF-/3
isoforms and fibronectin EDA+ in human renal allograft biopsies
with both acute and chronic rejection, and suggested that TGF-p
plays a role in the fibrosis of human chronic rejection [45]. In this
animal model of experimental chronic renal allograft rejection,
our findings demonstrate that the expression of TGF-J31 and
different matrix components is also increased. Specifically, we
detect an elevated mRNA expression of the proteoglycans bigly-
can and decorin and of type I collagen, and an increased
deposition, by immunofluorescence, of the glycoproteins tenascin
and fibronectin EDA+, and the proteoglycan decorin. TGF-f31
has been shown to directly induce the production of all these
matrix components [27—31]. Our results therefore suggest that the
increased TGF-1 expression leads to matrix accumulation. In
addition, we demonstrated an elevated mRNA expression of the
protease inhibitor PAl-I. The plasmin system is involved in matrix
degradation and is inhibited by PAl-i. TGF-j31 has been shown to
block matrix degradation by inducing PAT-i production [32, 331.
As a result, inhibition of matrix degradation represents an addi-
tional mechanism through which TGF-13 leads to matrix accumu-
lation in this model. We have previously shown that a similar
mechanism of increased matrix production and decreased degra-
dation under the influence of TGF-f31 leads to matrix accumula-
tion in experimental chronic cyclosporine nephrotoxicity [47].
The observed fibrosis in this model was associated with an
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Weeks after transplantation
Fig. 6. Quantitation of mRNA expression of type I collagen in allografis
relative to isograjls. Total RNA was isolated from whole cortex at weeks 4,
8, 24 and 52 and was hybridized with eDNA probes to type I collagen.
Band densities for GAPDH mRNA were used to control for differences in
total amount of RNA loaded onto each gel line. Values obtained for
allografts were then divided by values obtained for isografts and expressed
as fold-increase in mRNA. N = 5 for each group, P < 0.05, P < 0.01
and *** < 0.001 compared to isografts. Abbreviations are: A, allografts;
I, isografts.
increased deposition of the three major components of the ECM:
proteoglycans, glycoproteins, and collagens. Matrix deposition
was initially most marked in the interstitium and vessels. How-
ever, by 24 weeks, the changes were equally severe in all compart-
ments of the kidney, including a progressive increase in the
glomerular lesion and increased albuminuria. Significant albumin-
uria developed by eight weeks in the allografts and progressed
during the 52 weeks of observation. The isografts developed only
a mild and progressive degree of albuminuria and segmental
glomerulosclerosis. This is similar to renal ablation models in rats
where a simple reduction in renal mass has been shown to lead to
progressive albuminuria and glomerulosclerosis [481. The model
in this study was recently successfully reproduced and character-
ized by a number of investigators [21—25]. While Diamond et al
[21] showed a predominant glomerular lesion, we found not only
glomerular, but also tubulointerstitial and vascular changes, sim-
ilar to the human lesion of chronic rejection. The difference may
be related to variations in histocompatibility between breeding
stocks among different commercial suppliers.
Although not conclusive, the findings presented here, along
with our previous results, suggest that TGF-13 plays a causative
role in the matrix expansion that occurs in both human and
experimental chronic rejection. Matrix components induced by
TGF-f3, such as fibronectin EDA+ and tenascin, are preferen-
tially expressed in healing wounds and are up-regulated in this
model [49, 50]. Although TGF-j31 was previously shown to be
expressed in chronic rejection [22, 51], this is the first report to
demonstrate direct involvement of a growth factor in the deposi-
tion of ECM in experimental chronic rejection. A key feature of
wound repair is the necessity to terminate the process to avoid
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Fig. 7. Immunofluorescence micrographs of the expression of the glycoproteins tenascin and fibronectin and the proteoglycan decorin in allografts and
isografts. Kidncy sections from allografts (A to D, F to I, and K to N) and isografts (E, J, 0) obtained at weeks 4 (A, F, K), 8 (B, G, L), 24 (C, E, H,
J, M, 0) and 52 (D, I, N) were stained with an antibody to tenascin (A to F), fibronectin EDA+ (F to J), and decorin (K to 0). Photographs were taken
under identical conditions with equal exposures of 60 seconds. Magnification X250.
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Fig. 8. Quantitation of deposition of extracellidar
matrLx in allografts and isografts by
immunofluorescence. (A) Glomerular staining,
(B) tubulointerstitial staining, and (C) vessels
staining score at weeks 4, 8, 24 and 52.
Abbreviation is fibronectin EDA+, Fibro-
EDA+. Symbols are: () isografts 4 weeks; ()
allografts 4 weeks; () isografts 8 weeks; ()
allografts 8 weeks; () isografts 24 weeks; ()
allografts 24 weeks; (tilfi) isografts 52 weeks; ()
allografts 52 weeks; * < 0.05, **p < 0.01 and
***p < 0.1)01 compared to isografts.
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excessive scarring [52]. The development of fibrosis in chronic
renal allograft rejection suggests a failure to regulate or terminate
the process of tissue repair, resulting in continued activity of
TGF-13. TGF-13 is known to induce its own production [531, and its
persistent expression following repeated injuries leads, via posi-
tive feedback, to a cycle of continued TGF-13 production [27].
Since TGF-13 was elevated in both acute and chronic rejection, we
previously suggested that persistent up-regulation of TGF-p, a
result of acute rejection episodes, predisposes the graft to a cycle
of sustained TGF-13 expression and mediates the fibrosis of
chronic rejection [47]. It is likely that a similar mechanism
operates in this model in which an unabated TGF-pl overexpres-
sion may he responsible for excess matrix deposition and fibrosis.
Because the etiology of chronic rejection is likely multifactorial,
our study focused on the factors responsible for the progression of
fibrosis. There are data to suggest that both immunological and
non-immunological processes contribute to the etiology of chronic
rejection [21—25]. What causes the elevation of TGF-j3 in this
model remains unclear, When considering TGF-p in relation to
allograft pathology, two aspects of its biological properties are
particularly relevant: first, the ability of TGF-p to regulate ECM
production [28—34], and second, the immunomodulatory func-
tions of TGF-13. TGF-f3 is thought to be involved in the inflam-
matory response from onset to resolution and has important
immunosuppressive actions [26, 35, 36]. These immunosuppres-
sive activities are likely to explain the excessive inflammation that
results in the absence of the TGF-/31 gene [36]. We can speculate
that TGF-f3 expression may be increased in this model, not only as
a result of injury, but also as a reflection of the donor or graft cells
to attempt to induce graft tolerance. However, a number of
factors may also influence the development of chronic rejection in
this model including ischemia time, decreased nephron mass,
disorders of lipoprotein metabolism, and the nephrotoxic effects
of cyclosporine [14, 25, 47, 54]. In this 52 week model, cyclospo-
rine was administered for only 10 days, which is a relatively short
period of time for chronic cyclosporine nephrotoxicity to develop.
As a result, its contribution to fibrosis seems unlikely, although it
cannot be definitely ruled out.
In summary, our data suggest that the observed ECM accumu-
lation in this model of chronic rejection likely involves the dual
action of TGF-pl, not only on ECM deposition, but also on ECM
degradation. It is unknown whether blocking TGF-/3 overexpres-
sion with specific antagonists can ameliorate the fibrotic lesion of
chronic rejection and improve renal allograft function. Future
studies using TGF-p antagonists will help elucidate this important
question.
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